Cargando…

Kinase inhibitors in thyroid cancers

OBJECTIVE: The treatment landscape for thyroid cancers has changed rapidly with the availability of kinase inhibitors against VEGFR, BRAF, MEK, NTRK, and RET. We provide an up-to-date review of the role of kinase inhibitors in thyroid cancer and discuss upcoming trials. DESIGN & METHODS: A compr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sukrithan, Vineeth, Jain, Prachi, Shah, Manisha H, Konda, Bhavana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305552/ https://www.ncbi.nlm.nih.gov/pubmed/37434642 http://dx.doi.org/10.1530/EO-22-0062

Ejemplares similares

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib
por: Sukrithan, Vineeth, et al.
Publicado: (2023)

Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer
por: Nabhan, Fadi, et al.
Publicado: (2021)

The Role of the Kinase Inhibitors in Thyroid Cancers
por: Cuomo, Francesca, et al.
Publicado: (2022)

Pancreatic Cancer Heralded by Worsening Glycemic Control: A Report of Two Cases
por: Desai, Dimpi, et al.
Publicado: (2017)

Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience
por: Pešorda, Matea, et al.
Publicado: (2020)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Systemic mastocytosis presenting as cardiac tamponade with CD25(+) pericardial mast cells
por: Sukrithan, Vineeth K., et al.
Publicado: (2016)

Kinase inhibitors for advanced medullary thyroid carcinoma
por: Schlumberger, Martin, et al.
Publicado: (2012)

The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors
por: Ancker, Ole Vincent, et al.
Publicado: (2017)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

The Possible Role of Cancer Stem Cells in the Resistance to Kinase Inhibitors of Advanced Thyroid Cancer
por: Gianì, Fiorenza, et al.
Publicado: (2020)

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
por: Ragusa, Francesca, et al.
Publicado: (2022)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
por: Fukuda, Naoki, et al.
Publicado: (2021)

Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review
por: De Leo, Aurora, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022)

Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer
por: Mishra, Prachi, et al.
Publicado: (2021)

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
por: Kaae, Anne Christine, et al.
Publicado: (2021)

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Kinase Inhibitors and Ovarian Cancer
por: Katopodis, Periklis, et al.
Publicado: (2019)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment
por: Zhang, Ke, et al.
Publicado: (2023)

Rho Kinase Inhibitors as a Neuroprotective Pharmacological Intervention for the Treatment of Glaucoma
por: Thomas, Nisha M, et al.
Publicado: (2022)

Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates
por: Lorusso, L., et al.
Publicado: (2021)

Tyrosine kinase inhibitors induced thyroid dysfunction: myth or reality?
por: Malhotra, Anjli, et al.
Publicado: (2023)

Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem Cells
por: Bozorg-Ghalati, Farzaneh, et al.
Publicado: (2017)

Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer
por: Pozo, Karine, et al.
Publicado: (2018)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
por: Dervisis, Nikolaos, et al.
Publicado: (2016)

Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012)

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
por: Ratajczak, Maciej, et al.
Publicado: (2021)

How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer
por: Prazeres, Hugo, et al.
Publicado: (2011)

Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
por: Viganò, Mauro, et al.
Publicado: (2023)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
por: Peng, Chunying, et al.
Publicado: (2021)

Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer
por: Grela-Wojewoda, Aleksandra, et al.
Publicado: (2022)

Perspectives of the AMP-activated kinase (AMPK) signalling pathway in thyroid cancer
por: Andrade, Bruno Moulin, et al.
Publicado: (2014)

MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data
por: Schubert, Louis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cqderg88seflcbnk6gbrmk5v46